Analysis of prostrate-specific immunity in stage III and IV prostate cancer patients

Analysis of prostrate-specific immunity in stage III and IV prostate cancer patients - Analysis of prostate-specific immunity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32487

Enrollment

Registered

2009-02-06

Start date

2009-01-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Histologically or cytologically proven stage III or IV prostate carcinoma • Age above 18 years • PSA increase and/or CT/MRI confirmed progressive disease under antiandrogen treatment (including LH-RH analogues) • Performance score: WHO 0,1 or 2 at the time of study entry • Written informed consent

Exclusion criteria

Exclusion criteria: • Concurrent treatment with immunosuppressive drugs incl. corticosteroids • Undergoing any treatment other than antiandrogen therapy • Severe anemia (Hb

Design outcomes

Primary

Measure	Time frame
Do advanced stage prostate cancer patients have circulating prostate (cancer)-specific T-lymphocytes	—

Secondary

Measure	Time frame
What are the prostate (cancer) proteins that are being recognized by the T-lymphocytes	—

Countries

Netherlands

Outcome results